Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase II Study of Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

NCT05030077 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT05030077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase II Study of Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2021
Completion date
September 1, 2024
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, antineoplastic agents, carboplatin, cisplatin, gemcitabine, urogenital neoplasms, urothelial carcinoma